KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Common Equity (2016 - 2025)

Historic Common Equity for NovoCure (NVCR) over the last 12 years, with Q3 2025 value amounting to $341.3 million.

  • NovoCure's Common Equity fell 539.05% to $341.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $341.3 million, marking a year-over-year decrease of 539.05%. This contributed to the annual value of $360.2 million for FY2024, which is 63.92% down from last year.
  • NovoCure's Common Equity amounted to $341.3 million in Q3 2025, which was down 539.05% from $349.4 million recorded in Q2 2025.
  • NovoCure's 5-year Common Equity high stood at $445.4 million for Q3 2022, and its period low was $341.3 million during Q3 2025.
  • Moreover, its 5-year median value for Common Equity was $393.7 million (2023), whereas its average is $392.4 million.
  • As far as peak fluctuations go, NovoCure's Common Equity skyrocketed by 5380.74% in 2021, and later tumbled by 1783.3% in 2023.
  • NovoCure's Common Equity (Quarter) stood at $410.5 million in 2021, then grew by 7.47% to $441.2 million in 2022, then fell by 17.83% to $362.5 million in 2023, then dropped by 0.64% to $360.2 million in 2024, then dropped by 5.23% to $341.3 million in 2025.
  • Its Common Equity was $341.3 million in Q3 2025, compared to $349.4 million in Q2 2025 and $362.0 million in Q1 2025.